. . "The effective amount will vary depending upon the particular disease or syndrome to be treated or alleviated, as well as other factors including the age and weight of the patient, how advanced the disease etc state is, the general health of the patient, the severity of the symptoms, and whether the isoform specific antagonist of PAK kinase is being administered alone or in combination with other t" . . .